title: [Extracorporeal treatment of nucleoprotein disposal disorders using the systemic lupus erythematosus model: evaluation of efficacy and safety in a short-term simulated experiment].
abstract: Efficacy and safety of the extracorporeal blood perfusion through DNase I- and C1q-containing magnetic beads have been evaluated using the experimental model simulating the nucleoprotein disposal disorders in systemic lupus erythematosus (SLE). The study was performed using 20 rats in which the essential impairments of nucleoprotein catabolism typical for SLE were modeled. The animals were randomized into the experimental group and the placebo perfusion control group. Rats of the experimental group were characterized by the statistically significant reduction of increased levels of circulating immune complexes and plasma DNA as well as diminished levels of plasma creatinine and kidney IgG deposition as compared with placebo controls. During short-term experiment there were neither animal deaths nor substantial blood cell destruction and hepatotoxicity signs.
authors.affiliation: Research Institute for Clinical and Experimental Rheumatology RAMS.
authors.forename: A S
authors.initials: AS
authors.lastname: Trofimenko
authors.affiliation: Research Institute for Clinical and Experimental Rheumatology RAMS.
authors.forename: I P
authors.initials: IP
authors.lastname: Gontar
authors.affiliation: Volgograd State Medical University, Volgograd, Russia.
authors.forename: O V
authors.initials: OV
authors.lastname: Paramonova
authors.affiliation: Research Institute for Clinical and Experimental Rheumatology RAMS, Volgograd, Russia.
authors.forename: E S
authors.initials: ES
authors.lastname: Simakova
authors.affiliation: Research Institute for Clinical and Experimental Rheumatology RAMS, Volgograd, Russia.
authors.forename: I A
authors.initials: IA
authors.lastname: Zborovskaya
mesh_terms: D000818:Animals; D000974:Antibodies, Antinuclear / Q000097:blood*; D000936:Antigen-Antibody Complex / Q000097:blood*; D002417:Cattle; D015922:Complement C1q / Q000008:administration & dosage / Q000737:chemistry; D003404:Creatinine / Q000097:blood; D004247:DNA / Q000097:blood* / Q000276:immunology; D003850:Deoxyribonuclease I / Q000008:administration & dosage / Q000737:chemistry; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007260:Infusion Pumps; D007668:Kidney / Q000737:chemistry / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D059346:Magnets; D008863:Microspheres; D009698:Nucleoproteins / Q000097:blood* / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D000974:Antibodies, Antinuclear; D000936:Antigen-Antibody Complex; D007074:Immunoglobulin G; D009698:Nucleoproteins; D015922:Complement C1q; D004247:DNA; D003404:Creatinine; D003850:Deoxyribonuclease I
keywords: C1q; DNase I; biosimulation; extracorporeal therapy; systemic lupus erythematosus